Promoting Transparency in Pharmaceutical Industry–Sponsored Research

Bibliographic Data

ID11028312
AuthorsJames Stirling Ro (0000-0002-9218-3320, Robert Wood Johnson Foundation), Joseph S Ross (Joseph S. Ross is with the Section of General Internal Medicine, Yale University School of Medicine and Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, CT. Cary P. Gross is with the Section of General Internal Medicine and Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine. Harlan M. Krumholz is with the Section of Cardiovascular Medicine and Robert Wood Johnson Clinical Scholars Program and Section of Health Policy and Administration, Yale...), Cary P Gross (0000-0002-4974-935X, Joseph S. Ross is with the Section of General Internal Medicine, Yale University School of Medicine and Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, CT. Cary P. Gross is with the Section of General Internal Medicine and Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine. Harlan M. Krumholz is with the Section of Cardiovascular Medicine and Robert Wood Johnson Clinical Scholars Program and Section of Health Policy and Administration, Yale...), Harlan M Krumholz (0000-0003-2046-127X, Joseph S. Ross is with the Section of General Internal Medicine, Yale University School of Medicine and Center for Outcomes Research and Evaluation, Yale–New Haven Hospital, New Haven, CT. Cary P. Gross is with the Section of General Internal Medicine and Robert Wood Johnson Clinical Scholars Program, Yale University School of Medicine. Harlan M. Krumholz is with the Section of Cardiovascular Medicine and Robert Wood Johnson Clinical Scholars Program and Section of Health Policy and Administration, Yale...)
Year2012
Volume102
Issue1
Pages72-80
Publication date2012-01-01
Open AccessNo
TypeARTICLE
VenueAmerican Journal of Public Health (JOURNAL)
Journal identifiersISSN: 0090-0036 • E-ISSN: 1541-0048
PublisherAmerican Public Health Association (PUBLISHER • US)
DOI10.2105/ajph.2011.300187
PMID22095335
OpenAlexW2169875015
LanguageEN
Citations received7
References cited70

Strong, evidence-based practice requires that objective, unbiased research be available to inform individual clinical decisions, systematic reviews, meta-analyses, and expert guideline recommendations. Industry has used seeding trials, publication planning, messaging, ghostwriting, and selective publication and reporting of trial outcomes to distort the medical literature and undermine clinical trial research by obscuring information relevant to patients and physicians. Policies that promote transparency in the clinical trial research process, through improved and expanded disclosure of investigator contributions and funding, comprehensive publicly available trial registration, and independent analysis of clinical trial data analysis may address these subversive practices by improving accountability among industry and investigators. Minimizing marketing's impact on clinical trial research and strengthening the science will protect medical literature's integrity and the public's health

Accountability · Alternative medicine · Business · Clinical trial · Family medicine · Guideline · Medical education · MEDLINE · Pharmaceutical industry · Political science · Public health · Public relations · Systematic review · Transparency (behavior) · Ethics in Clinical Research · Medicine · Meta-analysis and systematic reviews · Nursing · Pharmaceutical industry and healthcare · Pharmacology

Tools

Open DOIOpen Access